Condition: Mitral Valve Prolapse · Ventricular Arrhythmias and Cardiac Arrest · Sponsor: Oslo University Hospital
FLECAPRO is a randomized controlled crossover trial assessing the effect and safety of adding flecainide to standard beta-blocker therapy to reduce the burden of ventricular arrhythmias in patients with arrhythmic mitral valve prolapse. The primary endpoint of will be assessed using an implantable loop recorder with blinded endpoint adjudication.
This description comes directly from the study's public registry record.
Eivind W Aabel, MD PhD · 41243148 · eivind.westrum.aabel@gmail.com
Always discuss trial participation with your own doctor first.
| Oslo University Hospital Rikshospitalet | Oslo, Norway | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05631730